Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135100158> ?p ?o ?g. }
- W2135100158 endingPage "3343" @default.
- W2135100158 startingPage "3328" @default.
- W2135100158 abstract "OBJECTIVE: To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide. OUTCOMES: Outcomes of interest include breast cancer incidence, breast cancer–specific survival, overall survival, and net health benefit. EVIDENCE: A comprehensive, formal literature review was conducted for relevant topics. Testimony was collected from invited experts and interested parties. The American Society of Clinical Oncology (ASCO) prescribed technology assessment procedure was followed. VALUES: More weight was given to published randomized trials. BENEFITS/HARMS: A woman’s decision regarding breast cancer risk reduction strategies is complex and will depend on the importance and weight attributed to information regarding both cancer- and noncancer-related risks and benefits. CONCLUSIONS: For women with a defined 5-year projected breast cancer risk of ≥ 1.66%, tamoxifen (at 20 mg/d for 5 years) may be offered to reduce their risk. Risk/benefit models suggest that greatest clinical benefit with least side effects is derived from use of tamoxifen in younger (premenopausal) women (who are less likely to have thromboembolic sequelae and uterine cancer), women without a uterus, and women at higher breast cancer risk. Data do not as yet suggest that tamoxifen provides an overall health benefit or increases survival. In all circumstances, tamoxifen use should be discussed as part of an informed decision-making process with careful consideration of individually calculated risks and benefits. Use of tamoxifen combined with hormone replacement therapy or use of raloxifene, any aromatase inhibitor or inactivator, or fenretinide to lower the risk of developing breast cancer is not recommended outside of a clinical trial setting. This technology assessment represents an ongoing process and recommendations will be updated in a timely matter. VALIDATION: The conclusions were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors. SPONSOR: American Society of Clinical Oncology." @default.
- W2135100158 created "2016-06-24" @default.
- W2135100158 creator A5004840750 @default.
- W2135100158 creator A5005775817 @default.
- W2135100158 creator A5022553586 @default.
- W2135100158 creator A5044875947 @default.
- W2135100158 creator A5053881786 @default.
- W2135100158 creator A5055301443 @default.
- W2135100158 creator A5065891328 @default.
- W2135100158 creator A5070245248 @default.
- W2135100158 creator A5079171882 @default.
- W2135100158 creator A5084247608 @default.
- W2135100158 date "2002-08-01" @default.
- W2135100158 modified "2023-09-28" @default.
- W2135100158 title "American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition" @default.
- W2135100158 cites W1487246579 @default.
- W2135100158 cites W1562190372 @default.
- W2135100158 cites W1595797072 @default.
- W2135100158 cites W1767142813 @default.
- W2135100158 cites W1773789492 @default.
- W2135100158 cites W1846149924 @default.
- W2135100158 cites W1908265239 @default.
- W2135100158 cites W1910259686 @default.
- W2135100158 cites W1920126165 @default.
- W2135100158 cites W1966623655 @default.
- W2135100158 cites W1968757839 @default.
- W2135100158 cites W1971022488 @default.
- W2135100158 cites W1975941800 @default.
- W2135100158 cites W1980540383 @default.
- W2135100158 cites W1985160737 @default.
- W2135100158 cites W1986364825 @default.
- W2135100158 cites W1990582579 @default.
- W2135100158 cites W1996164446 @default.
- W2135100158 cites W1996270518 @default.
- W2135100158 cites W2003996771 @default.
- W2135100158 cites W2006669125 @default.
- W2135100158 cites W2009074196 @default.
- W2135100158 cites W2011661086 @default.
- W2135100158 cites W2022689447 @default.
- W2135100158 cites W2023102019 @default.
- W2135100158 cites W2025148249 @default.
- W2135100158 cites W2029583845 @default.
- W2135100158 cites W2033106148 @default.
- W2135100158 cites W2034439633 @default.
- W2135100158 cites W2037632084 @default.
- W2135100158 cites W2048105386 @default.
- W2135100158 cites W2049042206 @default.
- W2135100158 cites W2049555849 @default.
- W2135100158 cites W2051034159 @default.
- W2135100158 cites W2052412363 @default.
- W2135100158 cites W2055066527 @default.
- W2135100158 cites W2055908359 @default.
- W2135100158 cites W2061563075 @default.
- W2135100158 cites W2064671008 @default.
- W2135100158 cites W2067864872 @default.
- W2135100158 cites W2078303139 @default.
- W2135100158 cites W2079777965 @default.
- W2135100158 cites W2080886948 @default.
- W2135100158 cites W2084030961 @default.
- W2135100158 cites W2089924367 @default.
- W2135100158 cites W2094809806 @default.
- W2135100158 cites W2101457306 @default.
- W2135100158 cites W2104926369 @default.
- W2135100158 cites W2107277934 @default.
- W2135100158 cites W2107308295 @default.
- W2135100158 cites W2110295371 @default.
- W2135100158 cites W2110467884 @default.
- W2135100158 cites W2112233548 @default.
- W2135100158 cites W2112796338 @default.
- W2135100158 cites W2113264115 @default.
- W2135100158 cites W2116459270 @default.
- W2135100158 cites W2118161058 @default.
- W2135100158 cites W2118473976 @default.
- W2135100158 cites W2119790019 @default.
- W2135100158 cites W2122748157 @default.
- W2135100158 cites W2124039325 @default.
- W2135100158 cites W2125678264 @default.
- W2135100158 cites W2128100826 @default.
- W2135100158 cites W2131722081 @default.
- W2135100158 cites W2133347950 @default.
- W2135100158 cites W2137775562 @default.
- W2135100158 cites W2139422964 @default.
- W2135100158 cites W2141647078 @default.
- W2135100158 cites W2141798191 @default.
- W2135100158 cites W2144624092 @default.
- W2135100158 cites W2146352023 @default.
- W2135100158 cites W2146569020 @default.
- W2135100158 cites W2149487349 @default.
- W2135100158 cites W2149921346 @default.
- W2135100158 cites W2153247110 @default.
- W2135100158 cites W2153877859 @default.
- W2135100158 cites W2154015002 @default.
- W2135100158 cites W2154842100 @default.
- W2135100158 cites W2156712240 @default.
- W2135100158 cites W2158429639 @default.
- W2135100158 cites W2159623447 @default.
- W2135100158 cites W2165594662 @default.
- W2135100158 cites W2165664908 @default.